Certara (NASDAQ:CERT) Sets New 52-Week High – Should You Buy?

Shares of Certara, Inc. (NASDAQ:CERT) reached a new 52-week high on Thursday. The company traded as high as $12.00 and last traded at $11.17, with a volume of 197,349 shares trading hands. The stock had previously closed at $11.09.

Certara News Summary

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara raised its 2026 revenue outlook to $427.2 million–$431.4 million, well above the cited analyst consensus of $380.9 million. Its EPS guidance of $0.31–$0.34 also met or exceeded the $0.31 consensus midpoint, giving investors a stronger forward outlook. Article: Certara Q3 2026 Earnings Call Highlights
• Positive Sentiment: Third-quarter revenue of $94.9 million topped the $92.0 million consensus, while EPS was reported at $0.09, meeting some estimates and exceeding others. Reports also highlighted double-digit software revenue growth—the first such pace in two years—which helped support a positive share-price reaction after the update. Article: Certara Q3 2026 earnings
• Neutral Sentiment: Barclays raised its price target from $9 to $12 but kept an Equal Weight rating, signaling improved valuation expectations without a bullish call. Article: Barclays price target update
• Negative Sentiment: UBS downgraded CERT from Buy to Neutral, though its $13 price target remains above the price cited in the report. The downgrade may restrain enthusiasm after the stock’s recent rally. Article: UBS downgrades Certara

Analyst Ratings Changes

A number of research firms have commented on CERT. UBS Group restated a “neutral” rating and set a $13.00 target price on shares of Certara in a research note on Friday. TD Cowen upped their price target on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings downgraded shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. KeyCorp lifted their target price on shares of Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Finally, Barclays upped their target price on shares of Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Certara currently has a consensus rating of “Hold” and a consensus target price of $9.92.

Certara Trading Down 1.1%

The stock has a fifty day moving average of $9.33 and a 200 day moving average of $7.35. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The company has a market capitalization of $1.84 billion, a PE ratio of -28.69 and a beta of 1.30.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, hitting the consensus estimate of $0.09. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The business had revenue of $94.90 million during the quarter, compared to the consensus estimate of $92.01 million. During the same period in the prior year, the company posted $0.14 EPS. The firm’s revenue for the quarter was down 9.3% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. As a group, sell-side analysts predict that Certara, Inc. will post 0.21 earnings per share for the current fiscal year.

Institutional Trading of Certara

Several hedge funds have recently bought and sold shares of the stock. Central Pacific Bank Trust Division increased its holdings in shares of Certara by 8.7% in the second quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after purchasing an additional 1,558 shares during the last quarter. GAMMA Investing LLC grew its holdings in Certara by 21.2% during the 3rd quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after buying an additional 1,710 shares in the last quarter. Sequoia Financial Advisors LLC increased its stake in Certara by 12.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock worth $117,000 after acquiring an additional 1,923 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Certara by 12.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock worth $133,000 after acquiring an additional 2,513 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Certara by 28.1% during the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after acquiring an additional 2,871 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.